Clinical study on the treatment of myocardial remodeling after acute myocardial infarction by integrated traditional Chinese and western medicine

Qilu Hospital of Shandong University0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•1. Aged 30 to 75 years;
•2. Emergency admission STEMI patients who meet the 4th edition of the global definition of AMI (cTnI peak value > 99% upper limit of the reference value (URL) and have an ascending and descending curve, and have clinical evidence of myocardial ischemia.
•3. All patients have received emergency PCI, and the infarct-related arterial TIMI blood flow classification has reached grade 3, within 10 days after PCI;
•4. Voluntarily participate in this study and have signed the informed consent.

•1. AMI combined with severe acute heart failure uncontrolled;
•2. AMI combined with cardiogenic shock (Killip grade >= grade III), who did not respond to vasopressors;
•3. AMI complicated with severe arrhythmia (sustained ventricular tachycardia, ventricular fibrillation), second-degree or higher atrioventricular block, and rapid atrial fibrillation;
•4. AMI complicated with mechanical complications (ventricular septal perforation, papillary muscle rupture, cardiac thrombus, ventricular free wall rupture);
•5. Severe systemic diseases (severe infection, massive hemorrhage due to anticoagulation and antithrombotics, respiratory failure);
•6. History of cerebral hemorrhage and cerebral aneurysm within 3 months;
•7. Severe hepatic and renal insufficiency [ALT >= 3 ULN (Upper Limit of Normal), Cr > 134µmol/L (2mg/dl) or eGFR < 45ml/min/1.73m2].
•8. Patients with neuropsychiatric diseases;
•9. Malignant tumor;
•10. Other pathophysiological states with expected survival less than 1 year;
•11. Those who are allergic to the components of the drug in this study;
•12. Pregnant or lactating women;
•13. Patients who participated in other clinical studies of traditional Chinese medicine within the first three months;
•14. Other diseases of clinical significance, etc., may cause serious danger to the patient.

发起方